At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical… [ Get More Details ]
Cost-effectiveness of TAVR in sSAS patients
Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY… [ Get More Details ]
In 2005, approximately 469,000 coronary artery bypass procedures were performed on 261,000 patients in the U.S.
[ Get More Details ]
Disease specific status and generic health status improvements from TAVR and SAVR
Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to… [ Get More Details ]